Precancerous Conditions Clinical Trial
Official title:
Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND
Verified date | September 2008 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Reduction in size and number of oral premalignant lesions
Status | Completed |
Enrollment | 42 |
Est. completion date | April 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 8mm oral premalignant lesion that has not been biopsied in the past 6 months Exclusion Criteria: - Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Pfizer Investigational Site | Ann Arbor | Michigan |
United States | Pfizer Investigational Site | Farmington | Connecticut |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Minneapolis | Minnesota |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | Shreveport | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL) | |||
Primary | by both clinical response (reduction in size of all lesions, | |||
Primary | prevention of growth in the index lesion and of any new lesions) | |||
Primary | and histological response (change in histological grade). | |||
Primary | To evaluate the safety of chronic multiple dosing of celecoxib in this patient population. | |||
Secondary | To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05215860 -
Photographic Evidence of Oral Precancerous Lesions in Current Tobacco and Areca Nut Users Improves Their Quit Rates
|
N/A | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT01752114 -
Early Diagnosis of Pulmonary Nodules
|
N/A | |
Completed |
NCT01752101 -
Identification of a Plasma Proteomic Signature for Lung Cancer
|
N/A | |
Completed |
NCT00314262 -
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
|
Phase 1/Phase 2 | |
Completed |
NCT00179361 -
Natural History of Oro-pharyngeal Cancer Precursors
|
N/A | |
Recruiting |
NCT06165614 -
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
|
Phase 1 | |
Not yet recruiting |
NCT01837693 -
Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2
|
N/A | |
Completed |
NCT00043615 -
Collection of Blood, Bone Marrow, Tumor or Tissue Samples
|
N/A | |
Active, not recruiting |
NCT02158858 -
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT02323672 -
Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions
|
N/A | |
Completed |
NCT00851305 -
Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy
|
N/A | |
Not yet recruiting |
NCT04065737 -
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
|
Phase 2 | |
Active, not recruiting |
NCT00655421 -
Oral Cancer Screening in Mumbai, India by Primary Health Care Workers
|
Phase 3 | |
Completed |
NCT00213603 -
Follow-up Modalities of Low Grade Precancerous Bronchial Lesions
|
N/A | |
Completed |
NCT03100045 -
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
|
Phase 1 |